Reproductive biology

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Tuesday, March 19, 2024
Research, Temperature, Health, Medicine, Frontiers Media, Menstrual cycle, IVY, Heart rate, Ovulation, Journal, Fertility, Pregnancy, Woman, Reproductive biology, Skin temperature, Machine learning, Menstruation, Map, Endocrinology, Birth control

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Retrieved on: 
Thursday, March 21, 2024
ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

Retrieved on: 
Wednesday, March 13, 2024
ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

ATLANTA, March 13, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces it will participate in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Axena Health Commends New Study Showing the Leva System’s Long-term Treatment Efficacy for Female Urinary Incontinence

Retrieved on: 
Tuesday, January 23, 2024
Women, Seniors, Physical Therapy, Health, FDA, Medical Devices, Health Technology, Consumer, Woman, Patient, Reproductive biology, Associate, MD, The Green Journal, Overactive bladder, Female, RCT, Harvard Medical School, Manager, FACS, PFMT, Urinary incontinence, University, Medicine, Quality of life, Risk, Incontinence, Food, Journal, FACOG, Storey, UI, Hospital, ACOG, Massachusetts General Hospital, American College, Birth control

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).

Key Points: 
  • Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).
  • “Two years of data showing that UI symptom relief endures following eight weeks of guided-PFMT offers compelling evidence that women can access first-line, conservative treatment successfully.
  • “This newest published study offers powerful evidence that women can access first-line treatment successfully, and that this treatment has a lasting effect.
  • “Pelvic floor muscle training is globally recommended first-line treatment for urinary incontinence,” said Eileen Maus, CEO of Axena Health.

Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

Retrieved on: 
Tuesday, December 19, 2023
Hospital, Woman, Ovarian cancer, Endometrioma, Dana–Farber Cancer Institute, MicroRNA, Brigham and Women's Hospital, MD, Doctor of Philosophy, Endometriosis, Assistant, Harvard Medical School, Gynaecology, Reproductive biology, Birth control

After a brief overview of the current treatment pathway for ovarian cancer and endometriosis, our panelists will provide an update on each of the company’s in-development products, including how each can close clinical gaps and improve health outcomes for women.

Key Points: 
  • After a brief overview of the current treatment pathway for ovarian cancer and endometriosis, our panelists will provide an update on each of the company’s in-development products, including how each can close clinical gaps and improve health outcomes for women.
  • Product updates will include upcoming milestones, pending publications, and future revenue potential for:
    The only commercially available ovarian cancer blood test for women diagnosed with an adnexal mass considered indeterminate or benign by initial clinical assessment.
  • A promising new blood test that combines Aspira’s proprietary protein biomarker technology with miRNAs licensed from the Dana Farber Cancer Institute.
  • The first protein biomarker test for the identification of ovarian endometriosis, including endometrioma.

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, November 30, 2023
Infertility, Lead, Hospital, Culture, Insemination, Case Western Reserve University, Division, Woman, University of California, Society, University, National Institutes of Health, Obstetrics, Reproductive medicine, Bangladesh Technical Education Board, American College, Publication, Patient, Gynaecology, Reproductive biology, Pharmaceutical industry

Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.

Key Points: 
  • Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®.
  • “With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women’s health procedures, Femasys stands apart in the industry,” said Dr. Liu.
  • He also served as the Division head, Reproductive Endocrinology and Infertility at the University of Cincinnati.
  • Ms. Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys, commented on the appointment of Dr. Liu, stating, “It is a great pleasure to welcome Dr. James Liu to Femasys as the Company’s next chief medical officer.

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Transfer, Assistant, Woman, Methodist Hospital, Research, Senior, Gynecologic Oncology (journal), Travel, University, Conference call, Risk, Gynaecology, Protein, MicroRNA, Dana–Farber Cancer Institute, Algorithm, Medical Affairs Bureau, Marketing, Metadata, AUP, COVID-19, Conference, Ovarian cancer, Harvard Medical School, University of Oxford, Brigham, CAB, Reproductive biology, Medical school, Aspira, Government, AACR, Hospital, Video game, Arms industry, Rare-earth element, Pharmaceutical industry, Birth control, Cryptocurrency, Obstetrics

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the three- and nine-month period ended September 30, 2023.

Key Points: 
  • “We are pleased to report another quarter of year-over-year growth, with revenues this quarter of $2.2 million.
  • The Company expects general and administrative expenses to remain flat for the fourth quarter of 2023.
  • Our cash balance this quarter benefited from the registered direct offering where we raised $4.7 million in gross proceeds.
  • The Company reiterates its operating cash utilization target for the second half of 2023 to between $6.0 million and $8.0 million.

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Retrieved on: 
Friday, November 17, 2023
Genetics, Research, Fertility, Disorder, WES, Assistant professor, History, Stem cell, Database, Male, Sophia Genetics, Intelligence, Infertility, Comprehension, IHG, NGS, Polish Academy of Sciences, Reproductive biology, GENETICS, Birth control

BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform.
  • IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.
  • Using the SOPHiA DDM™ Platform, IHG PAS will have analyzed results and streamlined insights in an efficient timeframe.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Retrieved on: 
Friday, November 17, 2023
Genetics, Research, Fertility, Disorder, WES, Assistant professor, History, Stem cell, Database, Male, Sophia Genetics, Intelligence, Infertility, Comprehension, IHG, NGS, Polish Academy of Sciences, Reproductive biology, GENETICS, Birth control

BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform.
  • IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.
  • Using the SOPHiA DDM™ Platform, IHG PAS will have analyzed results and streamlined insights in an efficient timeframe.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Retrieved on: 
Wednesday, October 25, 2023
Ovarian cancer, Research, Gynaecology, Harvard Medical School, Dana–Farber Cancer Institute, AACR, Assistant, MicroRNA, Conference, Protein, Poster, Reproductive biology, Serum, Aspira, Patient, Cancer, Metadata, Hospital, Medical imaging, Obstetrics, Brigham

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.

Key Points: 
  • AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.
  • The poster, entitled: “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.
  • The study combined serum protein and patient clinical information (metadata) from Aspria’s ovarian cancer registry studies with miRNA determined by the Elias laboratory.
  • The analysis shows the potential for improving ovarian cancer diagnostics by combining our trusted technology with miRNA.